SCHEMBL6103011

SCHEMBL6103011

CC#Cc1cccc(C=O)c1F

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ERN1 O75460 4/20 0.40
MEN1 O00255 1/20 0.38
LMNA P02545 1/20 0.38
THRB P10828 1/20 0.38
BLM P54132 1/20 0.38
KMT2A Q03164 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
ALDH1A1 P00352 1/20 0.36
TSHR P16473 1/20 0.36
TLR2 O60603 1/20 0.33
TLR1 Q15399 1/20 0.33
TLR6 Q9Y2C9 1/20 0.33
CA1 P00915 1/20 0.33
CA2 P00918 1/20 0.33
TRIM24 O15164 2/20 0.32
TRIM33 Q9UPN9 2/20 0.32
NPSR1 Q6W5P4 1/20 0.31
CYP2A6 P11509 1/20 0.31
CYP1A1 P04798 1/20 0.31
CYP1A2 P05177 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28422107 0.81 ERN1 (0.37) ERN1MEN1LMNATHRBBLM
SCHEMBL9699037 0.80 LMNA (0.50) ERN1MEN1LMNATHRBBLM
SCHEMBL29952034 0.77 ERN1 (0.42) ERN1MEN1LMNATHRBBLM
SCHEMBL20798207 0.77 ERN1 (0.42) ERN1MEN1LMNATHRBBLM
SCHEMBL32666059 0.77 ERN1 (0.42) ERN1MEN1LMNATHRBBLM
SCHEMBL5381815 0.77 ERN1 (0.42) ERN1MEN1LMNATHRBBLM
SCHEMBL6853865 0.75 KMT2A (0.58) ERN1MEN1LMNATHRBBLM
SCHEMBL4720705 0.74 ERN1 (0.36) ERN1MEN1LMNAKMT2ATDP1
SCHEMBL21795687 0.74 CES2 (0.35) CYP1A1CYP1A2CYP1B1
SCHEMBL7682759 0.74 CYP3A4 (0.51) LMNATDP1ALDH1A1TSHRCYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060040947-A1 Amino-heterocycles as vr-1 antagonists for treating pain MERCK SHARP & DOHME LTD. (GB) 2006-02-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060040947-A1 Amino-heterocycles as vr-1 antagonists for treating pain OPRL1, CNR1, GPR6 ERN1 2496/4885MEN1 4552/4885LMNA 4537/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.